uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
Goethe Univ, Dept Med, Hematol Oncol, Frankfurt, Germany.
Univ Milano Bicocca, San Gerardo Hosp, Pediat Clin, Monza, Italy.
Erasmus MC, Dept Immunol, Med Ctr Rotterdam, Rotterdam, Netherlands.
Univ Paris Diderot, Univ Hosp St Louis, Hematol Lab, Paris, France;Univ Paris Diderot, Univ Hosp St Louis, EA3518, Paris, France.
Vise andre og tillknytning
2019 (engelsk)Inngår i: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 33, nr 8, s. 1910-1922Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic leukemia (ALL) and is used for patient stratification and treatment decisions, but its precise role in Philadelphia chromosome positive ALL is less clear. This uncertainty results largely from methodological differences relating to the use of real-time quantitative PCR (qRT-PCR) to measure BCR-ABL1 transcript levels for MRD analysis. We here describe the first results by the EURO-MRD consortium on standardization of qRT-PCR for the e1a2 BCR-ABL1 transcript in Ph + ALL, designed to overcome the lack of standardisation of laboratory procedures and data interpretation. Standardised use of EAC primer/probe sets and of centrally prepared plasmid standards had the greatest impact on reducing interlaboratory variability. In QC1 the proportion of analyses with BCR-ABL1/ABL1 ratios within half a log difference were 40/67 (60%) and 52/67 (78%) at 10(-3) and 36/67 (53%) and 53/67 (79%) at 10(-4)BCR-ABL1/ABL1. Standardized RNA extraction, cDNA synthesis and cycler platforms did not improve results further, whereas stringent application of technical criteria for assay quality and uniform criteria for data interpretation and reporting were essential. We provide detailed laboratory recommendations for the standardized MRD analysis in routine diagnostic settings and in multicenter clinical trials for Ph + ALL.

sted, utgiver, år, opplag, sider
NATURE PUBLISHING GROUP , 2019. Vol. 33, nr 8, s. 1910-1922
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-393341DOI: 10.1038/s41375-019-0413-0ISI: 000479118400006PubMedID: 30858550OAI: oai:DiVA.org:uu-393341DiVA, id: diva2:1355292
Tilgjengelig fra: 2019-09-27 Laget: 2019-09-27 Sist oppdatert: 2019-09-27bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Hermansson, Monica

Søk i DiVA

Av forfatter/redaktør
Hermansson, Monica
Av organisasjonen
I samme tidsskrift
Leukemia

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 4 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf